Clinical Trials Browser

Phase 2 × Osteosarcoma × cabozantinib × Clear all

NCT02867592 2026-05-27

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

Phase 2 Active not recruiting

109 enrolled 24 charts

CNSEndocrineGastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Wilms Tumor, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Central Nervous System Neoplasms, Hepatoblastoma, Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part, Adrenocortical Carcinoma, Carcinoma, Medullary

NCT05019703 2026-04-17

Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study

Phase 2 Recruiting

Osteosarcoma

NCT02243605 2026-04-13

Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma

Phase 2 Active not recruiting

90 enrolled 15 charts

Sarcoma, Ewing, Osteosarcoma

NCT06341712 2026-03-31

CabOSTar

Phase 2 Terminated

Osteosarcoma

NCT05182164 2025-10-07

PEMBROCABOSARC

Phase 2 Recruiting

Sarcoma, Sarcoma, Ewing, Osteosarcoma, Histiocytoma, Malignant Fibrous

NCT05135975 2025-08-12

A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

Phase 2 Recruiting

CNSGenitourinarySarcoma

Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Rhabdoid Tumor